Symbols / EFTR $0.00 +0.00% eFFECTOR Therapeutics, Inc.
EFTR Chart
About
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Fundamentals
Scroll to Statements| Market Cap | 940.00 | Enterprise Value | -5.13M | Income | -34.63M | Sales | — | Book/sh | 0.21 | Cash/sh | 5.40 |
| Dividend Yield | — | Payout | 0.00% | Employees | 14 | IPO | — | P/E | — | Forward P/E | -0.00 |
| PEG | — | P/S | — | P/B | 0.00 | P/C | — | EV/EBITDA | 0.16 | EV/Sales | — |
| Quick Ratio | 0.99 | Current Ratio | 1.03 | Debt/Eq | 2448.37 | LT Debt/Eq | — | EPS (ttm) | -12.57 | EPS next Y | -2.25 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2024-05-09 | ROA | -83.33% | ROE | — | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.70M | Shs Float | 4.67M | Short Float | 1.97% |
| Short Ratio | 0.97 | Short Interest | — | 52W High | 0.01 | 52W Low | 0.00 | Beta | 0.89 | Avg Volume | 245.00 |
| Volume | 331.00 | Target Price | — | Recom | None | Prev Close | $0.00 | Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2024-02-06 | main | HC Wainwright & Co. | Buy → Buy | $24 |
- Why Is eFFECTOR Therapeutics (EFTR) Stock Up 75% Today? - InvestorPlace Fri, 26 May 2023 07
- Effector Therapeutics Stock Price Forecast. Should You Buy EFTR? - StockInvest.us hu, 09 Sep 2021 23
- 3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year - Yahoo Finance hu, 11 May 2023 07
- EFTR Stock Price and Chart — OTC:EFTR - TradingView Fri, 05 Jul 2024 23
- Latest EFTR News - eFFECTOR Therapeutics Announces it will Win... - Stock Titan Wed, 25 Aug 2021 23
- eFFECTOR Therapeutics Analyst Ratings and Price Targets | OTC:EFTR - Benzinga hu, 26 Aug 2021 20
- eFFECTOR Therapeutics Shares Jump After Clinical Update Of Investigational Cancer Drug - Yahoo Finance Fri, 06 Jan 2023 08
- Why Is Marvell Technology (MRVL) Stock Up 17% Today? - InvestorPlace Fri, 26 May 2023 07
- Indian Motorcycle and Super73 release a fast e-bike that won’t need a motorcycle license - Electrek Sat, 05 Mar 2022 08
- eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq - Yahoo Finance Mon, 24 Jun 2024 07
- Premal Patel Net Worth (2026) - GuruFocus Sun, 05 Mar 2023 01
- Why Is SunCar Technology (SDA) Stock Down 27% Today? - InvestorPlace Fri, 26 May 2023 07
- eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Yahoo Finance Mon, 29 Jan 2024 08
Financials
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
33.84
+4.45%
|
32.40
+1.59%
|
31.90
|
| Research And Development |
|
22.92
-1.69%
|
23.31
+16.82%
|
19.96
|
| Selling General And Administration |
|
10.93
-13.59%
|
12.64
-5.44%
|
13.37
|
| General And Administrative Expense |
|
10.93
-13.59%
|
12.64
-5.44%
|
13.37
|
| Other Gand A |
|
10.93
-13.59%
|
12.64
-5.44%
|
13.37
|
| Other Operating Expenses |
|
—
|
-3.55
-148.46%
|
-1.43
|
| Total Expenses |
|
33.84
+4.45%
|
32.40
+1.59%
|
31.90
|
| Operating Income |
|
-33.84
-4.45%
|
-32.40
-1.59%
|
-31.90
|
| Total Operating Income As Reported |
|
-33.84
-4.45%
|
-32.40
-1.59%
|
-31.90
|
| EBITDA |
|
-32.78
-61.00%
|
-20.36
-215.78%
|
17.59
|
| Normalized EBITDA |
|
-32.79
-0.93%
|
-32.48
-5.36%
|
-30.83
|
| Reconciled Depreciation |
|
0.11
+109.43%
|
0.05
+120.83%
|
0.02
|
| EBIT |
|
-32.89
-61.12%
|
-20.41
-216.24%
|
17.56
|
| Total Unusual Items |
|
0.01
-99.95%
|
12.12
-74.96%
|
48.42
|
| Total Unusual Items Excluding Goodwill |
|
0.01
-99.95%
|
12.12
-74.96%
|
48.42
|
| Special Income Charges |
|
0.01
-99.95%
|
12.12
-74.96%
|
48.42
|
| Other Special Charges |
|
—
|
—
|
0.49
|
| Restructuring And Mergern Acquisition |
|
-0.01
+99.95%
|
-12.12
+75.21%
|
-48.91
|
| Net Income |
|
-35.81
-58.00%
|
-22.66
-243.47%
|
15.80
|
| Pretax Income |
|
-35.81
-58.00%
|
-22.66
-243.47%
|
15.80
|
| Net Non Operating Interest Income Expense |
|
-1.95
-7.45%
|
-1.81
-3.07%
|
-1.76
|
| Interest Expense Non Operating |
|
2.92
+29.68%
|
2.25
+27.61%
|
1.76
|
| Net Interest Income |
|
-1.95
-7.45%
|
-1.81
-3.07%
|
-1.76
|
| Interest Expense |
|
2.92
+29.68%
|
2.25
+27.61%
|
1.76
|
| Interest Income Non Operating |
|
0.97
+121.41%
|
0.44
+7216.67%
|
0.01
|
| Interest Income |
|
0.97
+121.41%
|
0.44
+7216.67%
|
0.01
|
| Other Income Expense |
|
-0.02
-100.17%
|
11.55
-76.64%
|
49.45
|
| Other Non Operating Income Expenses |
|
-0.03
+95.47%
|
-0.57
-155.46%
|
1.03
|
| Tax Provision |
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
-100.00%
|
13.07
|
| Net Income Including Noncontrolling Interests |
|
-35.81
-58.00%
|
-22.66
-243.47%
|
15.80
|
| Net Income From Continuing Operation Net Minority Interest |
|
-35.81
-58.00%
|
-22.66
-243.47%
|
15.80
|
| Net Income From Continuing And Discontinued Operation |
|
-35.81
-58.00%
|
-22.66
-243.47%
|
15.80
|
| Net Income Continuous Operations |
|
-35.81
-58.00%
|
-22.66
-243.47%
|
15.80
|
| Normalized Income |
|
-35.82
-2.95%
|
-34.79
-77.97%
|
-19.55
|
| Net Income Common Stockholders |
|
-35.81
-58.00%
|
-22.66
-243.47%
|
15.80
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
0.00
|
| Diluted EPS |
|
-16.37
-19.05%
|
-13.75
-225.00%
|
11.00
|
| Basic EPS |
|
-16.37
-19.05%
|
-13.75
-152.38%
|
26.25
|
| Basic Average Shares |
|
2.19
+32.77%
|
1.65
+172.61%
|
0.60
|
| Diluted Average Shares |
|
2.19
+32.77%
|
1.65
+14.38%
|
1.44
|
| Diluted NI Availto Com Stockholders |
|
-35.81
-58.00%
|
-22.66
-243.47%
|
15.80
|
| Average Dilution Earnings |
|
—
|
—
|
0.00
|
| Line Item | Trend | 2023-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Assets |
|
20.54
-61.99%
|
54.06
|
| Current Assets |
|
19.84
-62.50%
|
52.90
|
| Cash Cash Equivalents And Short Term Investments |
|
18.37
-63.04%
|
49.70
|
| Cash And Cash Equivalents |
|
14.88
-70.07%
|
49.70
|
| Cash Equivalents |
|
—
|
49.70
|
| Other Short Term Investments |
|
3.50
|
0.00
|
| Prepaid Assets |
|
—
|
3.19
|
| Other Current Assets |
|
1.47
-54.04%
|
3.19
|
| Total Non Current Assets |
|
0.71
-39.14%
|
1.16
|
| Net PPE |
|
0.19
-24.90%
|
0.26
|
| Gross PPE |
|
0.52
+12.15%
|
0.46
|
| Accumulated Depreciation |
|
-0.32
-58.82%
|
-0.20
|
| Properties |
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.23
+21.47%
|
0.19
|
| Construction In Progress |
|
0.01
-81.08%
|
0.07
|
| Other Properties |
|
0.08
-57.65%
|
0.20
|
| Leases |
|
0.19
|
0.00
|
| Other Non Current Assets |
|
0.51
-43.19%
|
0.90
|
| Total Liabilities Net Minority Interest |
|
26.34
-28.37%
|
36.77
|
| Current Liabilities |
|
25.80
+548.47%
|
3.98
|
| Payables And Accrued Expenses |
|
3.66
+41.41%
|
2.59
|
| Payables |
|
2.33
+168.74%
|
0.87
|
| Accounts Payable |
|
2.33
+351.55%
|
0.52
|
| Current Accrued Expenses |
|
1.33
-22.62%
|
1.72
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.59
+18.17%
|
1.34
|
| Total Tax Payable |
|
—
|
0.35
|
| Income Tax Payable |
|
—
|
0.35
|
| Current Debt And Capital Lease Obligation |
|
20.55
+46593.18%
|
0.04
|
| Current Debt |
|
20.48
|
—
|
| Other Current Borrowings |
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.06
+36.36%
|
0.04
|
| Total Non Current Liabilities Net Minority Interest |
|
0.54
-98.34%
|
32.79
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
19.99
|
| Long Term Debt |
|
—
|
19.86
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.13
|
| Other Non Current Liabilities |
|
—
|
12.13
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
|
| Stockholders Equity |
|
-5.79
-133.53%
|
17.28
|
| Common Stock Equity |
|
-5.79
-133.53%
|
17.28
|
| Capital Stock |
|
0.00
-100.00%
|
0.00
|
| Common Stock |
|
0.00
-100.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
| Share Issued |
|
2.98
+84.62%
|
1.62
|
| Ordinary Shares Number |
|
2.98
+84.62%
|
1.62
|
| Treasury Shares Number |
|
0.01
-96.00%
|
0.30
|
| Additional Paid In Capital |
|
173.58
+25.62%
|
138.18
|
| Retained Earnings |
|
-179.38
-48.37%
|
-120.90
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
|
0.00
|
| Other Equity Adjustments |
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
-5.79
-133.53%
|
17.28
|
| Total Capitalization |
|
-5.79
-115.60%
|
37.14
|
| Working Capital |
|
-5.96
-112.18%
|
48.92
|
| Invested Capital |
|
14.69
-60.45%
|
37.14
|
| Total Debt |
|
20.55
+2.57%
|
20.03
|
| Net Debt |
|
5.61
|
—
|
| Capital Lease Obligations |
|
0.06
-64.71%
|
0.17
|
| Net Tangible Assets |
|
-5.79
-133.53%
|
17.28
|
| Tangible Book Value |
|
-5.79
-133.53%
|
17.28
|
| Derivative Product Liabilities |
|
0.04
-94.10%
|
0.68
|
| Interest Payable |
|
0.22
+67.67%
|
0.13
|
| Line Of Credit |
|
20.48
|
—
|
| Non Current Accrued Expenses |
|
0.50
|
—
|
| Line Item | Trend | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow |
|
-29.55
-14.10%
|
-25.90
-4.06%
|
-24.89
|
| Cash Flow From Continuing Operating Activities |
|
-29.55
-14.10%
|
-25.90
-4.06%
|
-24.89
|
| Net Income From Continuing Operations |
|
-35.81
-58.00%
|
-22.66
-243.47%
|
15.80
|
| Depreciation Amortization Depletion |
|
0.11
+109.43%
|
0.05
+120.83%
|
0.02
|
| Depreciation |
|
0.11
+109.43%
|
0.05
|
—
|
| Depreciation And Amortization |
|
0.11
+109.43%
|
0.05
+120.83%
|
0.02
|
| Other Non Cash Items |
|
0.35
+103.26%
|
-10.62
+78.14%
|
-48.59
|
| Stock Based Compensation |
|
4.59
-13.85%
|
5.33
-38.41%
|
8.66
|
| Operating Gains Losses |
|
-0.00
+99.53%
|
-0.64
-18.18%
|
-0.54
|
| Gain Loss On Investment Securities |
|
—
|
-0.64
+38.12%
|
-1.03
|
| Change In Working Capital |
|
1.69
-37.06%
|
2.68
+1224.79%
|
-0.24
|
| Change In Prepaid Assets |
|
0.59
-62.73%
|
1.57
+224.02%
|
-1.27
|
| Change In Payables And Accrued Expense |
|
0.91
+0.11%
|
0.91
-53.44%
|
1.95
|
| Change In Accrued Expense |
|
0.05
+200.00%
|
-0.05
-102.90%
|
1.79
|
| Change In Payable |
|
0.85
-10.75%
|
0.96
+518.06%
|
0.15
|
| Change In Account Payable |
|
0.85
-10.75%
|
0.96
+518.06%
|
0.15
|
| Change In Other Working Capital |
|
-0.00
-125.00%
|
0.00
+136.36%
|
-0.01
|
| Change In Other Current Assets |
|
0.19
+0.00%
|
0.19
+121.26%
|
-0.90
|
| Investing Cash Flow |
|
14.48
+181.10%
|
-17.86
-3261.06%
|
0.56
|
| Cash Flow From Continuing Investing Activities |
|
14.48
+181.10%
|
-17.86
-3261.06%
|
0.56
|
| Net PPE Purchase And Sale |
|
-0.10
+49.48%
|
-0.19
-133.98%
|
0.56
|
| Purchase Of PPE |
|
-0.10
+49.48%
|
-0.19
-357.14%
|
-0.04
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.61
|
| Capital Expenditure |
|
-0.10
+49.48%
|
-0.19
-357.14%
|
-0.04
|
| Net Investment Purchase And Sale |
|
14.58
+182.53%
|
-17.67
|
0.00
|
| Purchase Of Investment |
|
-17.17
+67.25%
|
-52.42
|
0.00
|
| Sale Of Investment |
|
31.75
-8.63%
|
34.75
|
0.00
|
| Financing Cash Flow |
|
21.23
+667.92%
|
2.77
-95.30%
|
58.81
|
| Cash Flow From Continuing Financing Activities |
|
21.23
+667.92%
|
2.77
-95.30%
|
58.81
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
5.89
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
19.84
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-13.94
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
19.84
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-13.94
|
| Net Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
5.89
|
| Net Common Stock Issuance |
|
21.18
+656.59%
|
2.80
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.06
+1766.67%
|
0.00
-94.64%
|
0.06
|
| Net Other Financing Charges |
|
—
|
-0.04
-100.07%
|
52.86
|
| Changes In Cash |
|
6.17
+115.04%
|
-40.99
-218.87%
|
34.49
|
| Beginning Cash Position |
|
8.71
-82.48%
|
49.70
+226.64%
|
15.22
|
| End Cash Position |
|
14.88
+70.82%
|
8.71
-82.48%
|
49.70
|
| Free Cash Flow |
|
-29.65
-13.63%
|
-26.09
-4.66%
|
-24.93
|
| Interest Paid Supplemental Data |
|
2.53
+38.73%
|
1.82
+36.04%
|
1.34
|
| Amortization Of Securities |
|
-0.47
-1178.38%
|
-0.04
|
0.00
|
| Common Stock Issuance |
|
21.18
+656.59%
|
2.80
|
0.00
|
| Issuance Of Capital Stock |
|
21.18
+656.59%
|
2.80
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|